IDEAS home Printed from https://ideas.repec.org/p/ohe/conres/002370.html
   My bibliography  Save this paper

The Lower Drug Costs Now Act and Pharmaceutical Innovation

Author

Listed:
  • Lou Garrison;Jake Hitch;Grace Hampson;Mireia Jofre-Bonet;Martina Garau;Graham Cookson

Abstract

The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on prescription drugs, one component of overall healthcare spending. Drug manufacturers would be required to negotiate prices with the US government, and prices would be capped at a level based on the prices of the drug in a set of foreign countries. Evaluation of a policy with such large potential impact on pharmaceutical revenues must consider potential negative effects on incentives to innovate. However, the relationship between prices (and revenues) and new drug approvals is uncertain, and there are significant limitations with the existing policy analysis. This short executive summary report summarises the methods and main insights from a study into the likely impacts of H.R. 3 on outcomes related to (bio)pharmaceutical innovation. The study consisted of two workstreams: 1) a set of interviews with key decision-makers in the pharmaceutical, biotechnology and healthcare investment industries, and 2) an expert elicitation exercise with academic and industry-oriented economists. After summarising the methods separately, the document concludes with the main insights across the two workstreams

Suggested Citation

  • Lou Garrison;Jake Hitch;Grace Hampson;Mireia Jofre-Bonet;Martina Garau;Graham Cookson, 2021. "The Lower Drug Costs Now Act and Pharmaceutical Innovation," Contract Research 002370, Office of Health Economics.
    • Handle: RePEc:ohe:conres:002370
    as

    Download full text from publisher

    File URL: https://www.ohe.org/publications/lower-drug-costs-now-act-and-pharmaceutical-innovation/attachment-v4_executive-summary-1-1-v2/
    Download Restriction: no
    ---><---

    More about this item

    Keywords

    The Lower Drug Costs Now Act and Pharmaceutical Innovation;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:conres:002370. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.